Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153470 (
Spleen
)
4,015
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Antibodies (Abs) specifically directed against the muscular
acetylcholine receptor
(
AChR
) mediate the pathogenesis of myasthenia gravis (MG). The animal model experimental autoimmune MG (EAMG) can be induced by passive transfer or by active immunization of anti-
AChR
Abs. We report a new EAMG mouse model that generates human anti-
AChR
Abs upon immunization with Torpedo
AChR
(tAChR). Mice transgenic for human mu, gamma1, and kappa germ line genes (HuMAb-Mice) were immunized with tAChR. Serum titers of anti-tAChR Abs were in the nanomolar range, and anti-rodent
AChR
Abs were in picomolar range. Some HuMAb-Mice had signs of muscle weakness, clearly indicating their susceptibility to EAMG. Human Ab-mouse
AChR
complexes were found at the neuromuscular junction, while
AChR
loss was up to 65%.
Spleen
and lymph nodes were used for producing hybridomas. Of the anti-tAChR monoclonal Ab-producing hybridomas, 2% had cross-reactivity with rodent
AChR
and none with human
AChR
. Immunization with a fusion protein, Trx-Halpha1-210, displaying the human main immunogenic region did not result in EAMG or the generation of human anti-human
AChR
monoclonal Abs. These experiments show that the HuMAb-Mouse represents a suitable model to generate and study the effects of human anti-
AChR
Abs in vivo.
...
PMID:Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. 1257 24
Autoantibodies to the muscle
acetylcholine receptor
(
AChR
) cause the symptoms of human and experimental myasthenia gravis (EMG).
AChR
-specific CD4+ T cells permit development of these diseases, but the role(s) of the Th1 and Th2 subsets is unclear. The STAT4 and STAT6 proteins, which mediate intracellular cytokine signaling, are important for differentiation of Th1 and Th2 cells, respectively. Wild-type (WT) BALB/c mice, which are prone to develop Th2 rather than Th1 responses to Ag, are resistant to EMG. We have examined the role of Th1 and Th2 cells in EMG using STAT4 (STAT4-/-)- or STAT6 (STAT6-/-)-deficient BALB/c mice. After
AChR
immunization, STAT6-/- mice were susceptible to EMG: they developed more serum anti-
AChR
Ab, and had more complement-fixing anti-
AChR
IgG2a and 2b and less IgG1 than WT or STAT4-/- mice. The susceptibility to EMG of STAT6-/- mice is most likely related to the Th1 cell-induced synthesis of anti-
AChR
Ab, which trigger complement-mediated destruction of the neuromuscular junction. CD4+ T cells of the STAT6-/- mice had proliferative responses to the
AChR
comparable to those of WT and STAT4-/- mice, and recognized similar
AChR
epitopes. STAT6-/- mice had abundant
AChR
-specific Th1 cells, which were nearly absent in WT and STAT4-/- mice.
Spleen
and lymph nodes from STAT6-/- mice contained cells that secreted IL-4 when cultured with
AChR
: these are most likely STAT6-independent cells, stimulated in a non-Ag-specific manner by the cytokines secreted by
AChR
-specific Th1 cells.
...
PMID:The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. 1468 14
Dendritic cells (DC) are usually regarded as antigen-presenting cells (APC) involved in T cell activation, but DC also directly or indirectly affect B cell function, antibody synthesis and isotype switch. In this study, we explore potential of DC-based immunotherapy in ongoing experimental autoimmune myasthenia gravis (EAMG) in Lewis rats, which is mediated by anti-
acetylcholine receptor
(
AChR
) antibodies.
Spleen
DC were isolated from onset of Lewis rat EAMG on day 39 post immunization (p.i.), exposed in vitro to IL-10 and then injected intraperitoneally into ongoing EAMG Lewis rats at dose of 1 x 10(6) cells/rat on day 5 p.i. with
AChR
+ complete Freund's adjuvant. IL-10-modified DC resulted in lower clinical scores, less body weight loss, lower numbers of anti-
AChR
IgG antibody-secreting cells and lower affinity of anti-
AChR
antibodies in rats receiving IL-10-modified DC, accompanied with lower expression of CD80 and CD86 and lower lymphocyte proliferation among lymph node mononuclear cells compared with control EAMG rats. Lower levels of IL-10 and IFN-gamma were also found in the supernatants of
AChR
-stimulated lymph node MNC culture in rats receiving IL-10-modified DC. These results demonstrate that IL-10-modified DC induced hypo-responsiveness by down-regulating co-stimulatory molecules, and reduced production of anti-
AChR
antibodies possibly by inhibiting IL-10 production. Importantly, this procedure that autologous DC from EAMG were adopted to treat ongoing EAMG is more close to clinical trial in human, encouraging future evaluation in human myasthenia gravis.
...
PMID:Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. 1519 2